RMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
RMD is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 and an impatient style. The stock is showing a mixed setup: pre-market strength is positive, but the broader technical picture is not a clean entry, options sentiment is bearish, and analysts have mostly trimmed price targets recently. I would not call this a clear buy at this moment; the better call is to hold and wait for a more convincing confirmation.
Current price is 209.28 in pre-market, up 2.88%, which is above the pivot level of 206.019 and near resistance at 210.408. MACD histogram is positive at 0.924 but contracting, which suggests momentum is still positive but weakening. RSI_6 at 33.816 is neutral-to-lagging and does not show strong bullish strength. Moving averages are converging, indicating a lack of a strong trend. Overall, the chart looks range-bound to slightly constructive, but not enough to justify an immediate aggressive buy.
["Pre-market price is up 2.88%, showing near-term buying interest.", "JPMorgan initiated coverage with an Overweight rating, reinforcing a favorable long-term thesis.", "KeyBanc still rates the stock Overweight and said underlying MedTech trends remain ahead of the market.", "ResMed remains viewed by analysts as a leader in sleep apnea treatment and CPAP therapy."]
["No news in the recent week, so there is no fresh event-driven catalyst supporting an immediate move.", "Several analysts lowered price targets recently, including Baird, Stifel, KeyBanc, Evercore ISI, and Citi.", "Options positioning is heavily bearish with a high put-call ratio.", "Technical momentum is not strong enough to confirm a breakout, with converging moving averages and RSI only neutral."]
No usable financial snapshot was provided because of an error, so latest-quarter growth trends cannot be confirmed from the supplied data. That said, analyst commentary references Q3 results and model updates, implying the latest quarter led to some estimate cuts and lower targets. Without the quarter-specific revenue, EPS, or margin data, the financial picture is incomplete, but the analyst revisions suggest expectations have softened.
Analyst sentiment is mixed to slightly positive, but the trend in price targets is downward. Baird lowered its target to $225 and kept Neutral, Stifel cut to $235 and kept Hold, KeyBanc cut to $290 but kept Overweight, Evercore ISI cut to $255 and kept Outperform, and Citi lowered to $340 while keeping Buy. The Wall Street pros view is that ResMed still has a strong long-term business, but near-term expectations have been trimmed. The pros are supportive on the franchise quality, while the cons are valuation pressure, softer target revisions, and limited upside urgency right now.
